ClinicalTrials.gg
CompletedNCT02628236Updated Sep 18, 2017Results posted

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

A Phase 2 interventional study of Aminolevulinic Acid (ALA) and BLU-U in Keratosis, Actinic, sponsored by DUSA Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-18.

Sponsored by DUSA Pharmaceuticals, Inc. (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic — 1 open to participants now, 2 under way, none of them phase 3. Aminolevulinic Acid · Keratosis, Actinic.

Enrollment
20th of 29
14 · median 32
Started
2016
with 1 other
Phase 2
11 of 29
none open now
Registered
15th of 29
by date
Lead sponsor
9 of 29
DUSA Pharmaceuticals, Inc.

Among the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, this one is the 20th largest by enrollment, is one of 2 that started in 2016, is one of 11 in phase 2, and was the 15th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

1 of the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Aminolevulinic Acid

Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) and protoporphyrin IX (PpIX) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.

03

Conditions studied

  • Keratosis, Actinic

Browse trials for

Keywords

  • Actinic keratosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 6 Grade 1/2 AKs on one upper extremity AND
  • At least 12 Grade 1/2 AKs on the OTHER upper extremity

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • history of cutaneous photosensitization, porphyria, to porphyrins or photodermatosis
  • lesions suspicious for skin cancer (skin cancer not ruled out by ) or untreated skin cancers within the Treatment Area
  • (BMI) > 32.0 kg/m2
  • skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy
  • significant blood loss within 60 days or donated blood/plasma within 72 hours prior to Visit 2 (Baseline)
  • tested positive at screening for (HIV) or was known to be seropositive for HIV
  • a history of lead poisoning or a history of a significant exposure to lead
  • tested positive at screening for surface antigen, antibody or had a history of a positive result
  • positive drug screen at Screening
  • Screening safety labs are in the opinion of the investigator
  • major surgery within 30 days prior to Visit 2 (Baseline) or plans to have surgery during the study
  • Subject is
  • currently enrolled in an drug or device study
  • has received an investigational drug or been treated with an investigational device within 30 days prior to Visit 2 (Baseline)
  • known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)
  • use of the following topical preparations on the extremities to be treated:

    • Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of initiation of treatment
    • Cryotherapy within 2 weeks of initiation of treatment
    • Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of initiation of treatment
    • Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment
  • use of systemic retinoid therapy within 6 months of initiation of treatment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    ALA

    20% aminolevulinic acid applied via Kerastick to individual AK lesions on the upper extremities and covered with occlusive dressing for 3 hours prior to BLU-U treatment

    Drug: Aminolevulinic Acid (ALA) · Device: BLU-U

Interventions

  • 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

    Also known as: Levulan Kerastick

  • DeviceBLU-U

    10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2

    Also known as: Blue Light Photodynamic Therapy (PDT)

06

What researchers measure

Primary outcomes

  1. Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA

    Maximum baseline corrected plasma concentration (Cmax) for ALA over the 24 hour sampling time period. Blood samples were taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.

    Time frame: 2 days

  2. Time at Which Cmax is Attained (Tmax) for ALA

    Time of the maximum baseline corrected plasma concentration for ALA measured at at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.If a maximum value occurred at more than one timepoint Tmax is defined as the first timepoint with this value.

    Time frame: 2 days

  3. AUCt

    AUCt is the area under the baseline corrected plasma concentration-time profile up to the last quantifiable/non-negative plasma concentration

    Time frame: 0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24 hours post-dose

  4. The Terminal Exponential Half-life (T1/2,z) for ALA

    The terminal slope was calculated by linear least squares regression of the log plasma concentration-time data. The terminal exponential half-life (T1/2,z) will be calculated as 0.693 divided by the absolute value of slope.

    Time frame: 2 days

  5. Maximum Baseline Corrected Plasma Concentration (Cmax) for PpIX

    Maximum baseline corrected plasma concentration (Cmax) for PpIX over the 48 hour sampling time period. Blood samples were taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.

    Time frame: 2 days

  6. Time at Which Cmax is Attained (Tmax) for PpIX

    Time of the maximum baseline corrected plasma concentration for PpIX measured at at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.If a maximum value occurred at more than one timepoint Tmax is defined as the first timepoint with this value.

    Time frame: 2 days

  7. AUCBL for PpIX

    The area under the concentration time-curve assuming the baseline observed plasma concentration existed from time 0 to tlast.

    Time frame: 0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours post-dose

  8. AUCt for PpIX

    The area under the observed plasma concentration time-curve from time 0 to the last quantifiable plasma concentration.

    Time frame: 0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours post-dose

  9. AUCt/AUCBL for PpIX

    The ratio of AUCt to AUCBL for PpIX

    Time frame: 0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours post-dose

Secondary outcomes

  1. Hyperpigmentation

    HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

    Time frame: Baseline

  2. Hyperpigmentation

    HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

    Time frame: 24 hours after PDT

  3. Hyperpigmentation

    HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

    Time frame: Week 4

  4. Hypopigmentation

    HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

    Time frame: Baseline

  5. Hypopigmentation

    HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

    Time frame: 24 hours after PDT

  6. Hypopigmentation

    HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

    Time frame: Week 4

  7. Erythema

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: Baseline

  8. Erythema

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: 5 Minutes after PDT

  9. Erythema

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: 24 hours after PDT

  10. Erythema

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: Week 4

  11. Edema

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: Baseline

  12. Edema

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: 5 Minutes after PDT

  13. Edema

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: 24 hours after PDT

  14. Edema

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: Week 4

  15. Stinging/Burning

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: Baseline

  16. Stinging/Burning

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: Intraprocedure

  17. Stinging/Burning

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: 5 Minutes after photodynamic therapy

  18. Stinging/Burning

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: 24 hours after PDT

  19. Stinging/Burning

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: Week 4

  20. Scaling and Dryness

    SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

    Time frame: Baseline

  21. Scaling and Dryness at Visit 4

    SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

    Time frame: 24 hours after PDT

  22. Scaling and Dryness

    SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

    Time frame: Week 4

  23. OOZING/VESICULATION/CRUSTING

    OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

    Time frame: Baseline

  24. OOZING/VESICULATION/CRUSTING

    OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

    Time frame: 24 hours after PDT

  25. OOZING/VESICULATION/CRUSTING

    OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

    Time frame: Week 4

07

Results

Posted Sep 18, 2017

Participant flow

Participant flow — Overall Study
MilestoneALA-PDT
Started14
Completed14
Not completed0

Outcome measures

PrimaryMaximum Baseline Corrected Plasma Concentration (Cmax) for ALA

Maximum baseline corrected plasma concentration (Cmax) for ALA over the 24 hour sampling time period. Blood samples were taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.

Time frame:
2 days
Reported as:
Geometric mean · ng/mL
Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA
ng/mLALA-PDT
Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA39.05 ± 319.7
PrimaryTime at Which Cmax is Attained (Tmax) for ALA

Time of the maximum baseline corrected plasma concentration for ALA measured at at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.If a maximum value occurred at more than one timepoint Tmax is defined as the first timepoint with this value.

Time frame:
2 days
Reported as:
Median · hours
Time at Which Cmax is Attained (Tmax) for ALA
hoursALA-PDT
Time at Which Cmax is Attained (Tmax) for ALA2 (0.25 to 36)
PrimaryAUCt

AUCt is the area under the baseline corrected plasma concentration-time profile up to the last quantifiable/non-negative plasma concentration

Time frame:
0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
AUCt
ng*hr/mLALA-PDT
AUCt182.1 ± 111.6
PrimaryThe Terminal Exponential Half-life (T1/2,z) for ALA

The terminal slope was calculated by linear least squares regression of the log plasma concentration-time data. The terminal exponential half-life (T1/2,z) will be calculated as 0.693 divided by the absolute value of slope.

Time frame:
2 days
Reported as:
Geometric mean · hours
The Terminal Exponential Half-life (T1/2,z) for ALA
hoursALA-PDT
The Terminal Exponential Half-life (T1/2,z) for ALA5.386 ± 253.7
PrimaryMaximum Baseline Corrected Plasma Concentration (Cmax) for PpIX

Maximum baseline corrected plasma concentration (Cmax) for PpIX over the 48 hour sampling time period. Blood samples were taken before ALA application and at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.

Time frame:
2 days
Reported as:
Median · ng/mL
Maximum Baseline Corrected Plasma Concentration (Cmax) for PpIX
ng/mLALA-PDT
Maximum Baseline Corrected Plasma Concentration (Cmax) for PpIX0.735 (0 to 2.3)
PrimaryTime at Which Cmax is Attained (Tmax) for PpIX

Time of the maximum baseline corrected plasma concentration for PpIX measured at at 15 and 30 minutes, 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours following study medication application.If a maximum value occurred at more than one timepoint Tmax is defined as the first timepoint with this value.

Time frame:
2 days
Reported as:
Median · hours
Time at Which Cmax is Attained (Tmax) for PpIX
hoursALA-PDT
Time at Which Cmax is Attained (Tmax) for PpIX12 (0.25 to 48)
PrimaryAUCBL for PpIX

The area under the concentration time-curve assuming the baseline observed plasma concentration existed from time 0 to tlast.

Time frame:
0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
AUCBL for PpIX
ng*hr/mLALA-PDT
AUCBL for PpIX77.34 ± 98.04
PrimaryAUCt for PpIX

The area under the observed plasma concentration time-curve from time 0 to the last quantifiable plasma concentration.

Time frame:
0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
AUCt for PpIX
ng*hr/mLALA-PDT
AUCt for PpIX77.00 ± 59.16
PrimaryAUCt/AUCBL for PpIX

The ratio of AUCt to AUCBL for PpIX

Time frame:
0, 15, 30 minutes, and 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours post-dose
Reported as:
Geometric mean · ratio
AUCt/AUCBL for PpIX
ratioALA-PDT
AUCt/AUCBL for PpIX0.9956 (0.831 to 1.19)
SecondaryHyperpigmentation

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame:
Baseline
Reported as:
Count of participants · Participants
Hyperpigmentation
ParticipantsALA-PDT
Grade 06
Grade 17
Grade 21
Grade 30
Grade 40
SecondaryHyperpigmentation

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame:
24 hours after PDT
Reported as:
Count of participants · Participants
Hyperpigmentation
ParticipantsALA-PDT
Grade 07
Grade 16
Grade 21
Grade 30
Grade 40
SecondaryHyperpigmentation

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame:
Week 4
Reported as:
Count of participants · Participants
Hyperpigmentation
ParticipantsALA-PDT
Grade 07
Grade 16
Grade 21
Grade 30
Grade 40
SecondaryHypopigmentation

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Time frame:
Baseline
Reported as:
Count of participants · Participants
Hypopigmentation
ParticipantsALA-PDT
Grade 08
Grade 16
Grade 20
Grade 30
Grade 40
SecondaryHypopigmentation

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Time frame:
24 hours after PDT
Reported as:
Count of participants · Participants
Hypopigmentation
ParticipantsALA-PDT
Grade 08
Grade 16
Grade 20
Grade 30
Grade 40
SecondaryHypopigmentation

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation Grade 4 = Marked hypopigmentation involving moderate or large sized areas

Time frame:
Week 4
Reported as:
Count of participants · Participants
Hypopigmentation
ParticipantsALA-PDT
Grade 08
Grade 16
Grade 20
Grade 30
Grade 40
SecondaryErythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
Baseline
Reported as:
Count of participants · Participants
Erythema
ParticipantsALA-PDT
Grade 011
Grade 11
Grade 22
Grade 30
Grade 40
SecondaryErythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
5 Minutes after PDT
Reported as:
Count of participants · Participants
Erythema
ParticipantsALA-PDT
Grade 04
Grade 12
Grade 25
Grade 33
Grade 40
SecondaryErythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
24 hours after PDT
Reported as:
Count of participants · Participants
Erythema
ParticipantsALA-PDT
Grade 00
Grade 13
Grade 24
Grade 37
Grade 40
SecondaryErythema

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
Week 4
Reported as:
Count of participants · Participants
Erythema
ParticipantsALA-PDT
Grade 07
Grade 16
Grade 21
Grade 30
Grade 40
SecondaryEdema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
Baseline
Reported as:
Count of participants · Participants
Edema
ParticipantsALA-PDT
Grade 014
Grade 10
Grade 20
Grade 30
Grade 40
SecondaryEdema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
5 Minutes after PDT
Reported as:
Count of participants · Participants
Edema
ParticipantsALA-PDT
Grade 08
Grade 15
Grade 21
Grade 30
Grade 40
SecondaryEdema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
24 hours after PDT
Reported as:
Count of participants · Participants
Edema
ParticipantsALA-PDT
Grade 08
Grade 13
Grade 23
Grade 30
Grade 40
SecondaryEdema

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
Week 4
Reported as:
Count of participants · Participants
Edema
ParticipantsALA-PDT
Grade 014
Grade 10
Grade 20
Grade 30
Grade 40
SecondaryStinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
Baseline
Reported as:
Count of participants · Participants
Stinging/Burning
ParticipantsALA-PDT
Grade 013
Grade 11
Grade 20
Grade 30
SecondaryStinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
Intraprocedure
Reported as:
Count of participants · Participants
Stinging/Burning
ParticipantsALA-PDT
Grade 00
Grade 16
Grade 28
Grade 30
SecondaryStinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
5 Minutes after photodynamic therapy
Reported as:
Count of participants · Participants
Stinging/Burning
ParticipantsALA-PDT
Grade 06
Grade 15
Grade 23
Grade 30
SecondaryStinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
24 hours after PDT
Reported as:
Count of participants · Participants
Stinging/Burning
ParticipantsALA-PDT
g10
Grade 14
Grade 20
Grade 30
SecondaryStinging/Burning

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
Week 4
Reported as:
Count of participants · Participants
Stinging/Burning
ParticipantsALA-PDT
Grade 013
Grade 11
Grade 20
Grade 30
SecondaryScaling and Dryness

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame:
Baseline
Reported as:
Count of participants · Participants
Scaling and Dryness
ParticipantsALA-PDT
Grade 012
Grade 12
Grade 20
Grade 30
Grade 40
SecondaryScaling and Dryness at Visit 4

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame:
24 hours after PDT
Reported as:
Count of participants · Participants
Scaling and Dryness at Visit 4
ParticipantsALA-PDT
Grade 09
Grade 13
Grade 21
Grade 31
Grade 40
SecondaryScaling and Dryness

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame:
Week 4
Reported as:
Count of participants · Participants
Scaling and Dryness
ParticipantsALA-PDT
Grade 09
Grade 15
Grade 20
Grade 30
Grade 40
SecondaryOOZING/VESICULATION/CRUSTING

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame:
Baseline
Reported as:
Count of participants · Participants
OOZING/VESICULATION/CRUSTING
ParticipantsALA-PDT
Grade 014
Grade 10
Grade 20
Grade 30
Grade 40
SecondaryOOZING/VESICULATION/CRUSTING

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame:
24 hours after PDT
Reported as:
Count of participants · Participants
OOZING/VESICULATION/CRUSTING
ParticipantsALA-PDT
Grade 013
Grade 11
Grade 20
Grade 30
Grade 40
SecondaryOOZING/VESICULATION/CRUSTING

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame:
Week 4
Reported as:
Count of participants · Participants
OOZING/VESICULATION/CRUSTING
ParticipantsALA-PDT
Grade 014
Grade 10
Grade 20
Grade 30
Grade 40

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALA-PDT0/14 (0%)1/14 (7.1%)0/14 (0%)
Most frequent serious events
Most frequent serious events
EventALA-PDT
deep vein thrombosisVascular disorders1/14

Baseline characteristics

Age, Continuous
Age, Continuous(years)ALA-PDT
Mean65.6 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)ALA-PDT
Female3
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ALA-PDT
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ALA-PDT
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)ALA-PDT
United States14
08

Study locations

2 sites
  • DermResearch, Inc.
    Austin, Texas 78759, United States
  • J&J Studies, Inc
    College Station, Texas 77845, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of May 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2015
First posted
Dec 11, 2015
Start
Feb 2016
Primary completionActual
May 2016
CompletionActual
Jul 2016
Results first posted
Sep 18, 2017
Last update
Sep 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02628236
Responsible party
Sponsor
First posted
Dec 11, 2015
Start date
Feb 2016
Primary completion
May 2016
Completion
Jul 2016
Results posted
Sep 18, 2017
Last update
Sep 18, 2017

Study contacts

Stuart Marcus, MD, PhD
study director · DUSA Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion